Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

L. Doherty, D. C. Gigas, S. Kesari, J. Drappatz, R. Kim, J. Zimmerman, L. Ostrowsky, P. Y. Wen

Research output: Contribution to journalArticle

146 Scopus citations

Abstract

Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.

Original languageEnglish (US)
Pages (from-to)156-158
Number of pages3
JournalNeurology
Volume67
Issue number1
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas'. Together they form a unique fingerprint.

  • Cite this

    Doherty, L., Gigas, D. C., Kesari, S., Drappatz, J., Kim, R., Zimmerman, J., Ostrowsky, L., & Wen, P. Y. (2006). Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology, 67(1), 156-158. https://doi.org/10.1212/01.wnl.0000223844.77636.29